SuperworthCalciMedica EPS CALC
Diluted earnings per share by quarter and over the last twelve months, from 2019.
- Last 12 months, to Jun 30, 2026
- −$6.75
- Latest quarter, Q2 FY26
- −$2.25
- Fiscal year 2025
- −$9.80
CalciMedica's earnings per share was −$6.75 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$2.25.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$9.80 | n/a |
| FY2024 | −$5.90 | n/a |
| FY2023 | −$130.40 | n/a |
| FY2022 | −$562.70 | n/a |
| FY2021 | −$118.30 | n/a |
| FY2019 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$2.25 | n/a | −$6.75 | |
| Q1 FY26 | $1.50 | n/a | −$6.50 | |
| Q4 FY25 | −$3.40 | n/a | −$9.80 | |
| Q3 FY25 | −$2.60 | n/a | −$8.05 | |
| Q2 FY25 | −$2.00 | n/a | −$7.95 | |
| Q1 FY25 | −$1.80 | −3700% | −$7.75 | |
| Q4 FY24 | −$1.65 | n/a | −$5.90 | |
| Q3 FY24 | −$2.50 | n/a | −$7.85 | |
| Q2 FY24 | −$1.80 | n/a | −$9.45 | |
| Q1 FY24 | $0.05 | n/a | −$13.20 | |
| Q4 FY23 | −$3.60 | −161% | −$130.40 | |
| Q3 FY23 | −$4.10 | n/a | −$120.90 |
Against its peers
Companies in Drug Manufacturers - General nearest CalciMedica's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| CALCCalciMedica | −$6.75 | |
| ATNMActinium Pharmaceuticals | $0.36 | |
| SPROSpero Therapeutics | $0.11 | |
| LFVNLifevantage | $0.40 | −46% a year |
| Peer median | $0.36 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on CalciMedica
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.